These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28455291)

  • 1. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
    Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
    Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
    Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
    Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Alsamman K; El-Masry OS
    Oncol Rep; 2018 Oct; 40(4):2157-2162. PubMed ID: 30106434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
    Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Wang J; Garbutt C; Ma H; Gao P; Hornicek FJ; Kan Q; Shi H; Duan Z
    Gynecol Oncol; 2018 Jul; 150(1):143-150. PubMed ID: 29699801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.
    Yu H; Su J; Xu Y; Kang J; Li H; Zhang L; Yi H; Xiang X; Liu F; Sun L
    Eur J Cancer; 2011 Jul; 47(10):1585-94. PubMed ID: 21371883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
    Chen J; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced RBPMS Levels Promote Cell Proliferation and Decrease Cisplatin Sensitivity in Ovarian Cancer Cells.
    Rabelo-Fernández RJ; Santiago-Sánchez GS; Sharma RK; Roche-Lima A; Carrion KC; Rivera RAN; Quiñones-Díaz BI; Rajasekaran S; Siddiqui J; Miles W; Rivera YS; Valiyeva F; Vivas-Mejia PE
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation.
    Battista RA; Resnati M; Facchi C; Ruggieri E; Cremasco F; Paradiso F; Orfanelli U; Giordano L; Bussi M; Cenci S; Milan E
    PLoS One; 2018; 13(8):e0201621. PubMed ID: 30067838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system.
    Xia M; Yu H; Gu S; Xu Y; Su J; Li H; Kang J; Cui M
    Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
    Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
    Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
    Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
    Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
    Noriega-Rivera R; Rivera-Serrano M; Rabelo-Fernandez RJ; Pérez-Santiago J; Valiyeva F; Vivas-Mejía PE
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGF19 promotes cell autophagy and cisplatin chemoresistance by activating MAPK signaling in ovarian cancer.
    Zhu W; Huang M; Thakur A; Yan Y; Wu X
    PeerJ; 2023; 11():e14827. PubMed ID: 36751636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.